Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 8/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 8/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 8/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771250 | 0.84 | CACNA2D1 (0.51) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL771132 | 0.83 | POLB (0.40) | MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL770148 | 0.83 | POLB (0.40) | MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL770150 | 0.83 | POLB (0.40) | MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL770641 | 0.81 | CHRM2 (0.35) | MEN1LMNAKMT2AALDH1A1MAPK1 | |
| SCHEMBL770821 | 0.81 | AR (0.50) | MEN1LMNAKMT2AALDH1A1MAPK1 | |
| SCHEMBL770815 | 0.80 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL770874 | 0.80 | NPC1 (0.47) | MEN1LMNAKMT2AALDH1A1MAPK1 | |
| SCHEMBL770676 | 0.79 | L3MBTL1 (0.48) | MEN1LMNAGAAKMT2AALDH1A1 | |
| SCHEMBL770972 | 0.79 | HDAC1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822452-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2014-09-02 | — | — | US | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | CACNA2D1 3305/4885CACNA1B 3651/4885CACNB1 4111/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | CACNA2D1 3302/4885CACNA1B 3638/4885CACNB1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.